Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

U.S. FTC reaches pay-for-delay settlement with Endo

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/23/2017 | 10:53pm CET
The Allergan logo is seen in this photo illustration

Endo International Plc (>> Endo International PLC) said on Monday it had reached a proposed settlement with U.S. anti-trust regulators under which it will not pay rivals to delay the introduction of generic competitors to its medications.

Endo International Plc (>> Endo International PLC) said on Monday it had reached a proposed settlement with U.S. anti-trust regulators under which it will not pay rivals to delay the introduction of generic competitors to its medications.

The Federal Trade Commission had alleged Endo paid Impax Laboratories Inc (>> Impax Laboratories Inc) to delay the introduction of a generic version of its painkiller Opana ER.

The agency also alleged Endo paid Watson Laboratories Inc to delay introduction of a generic version of its Lidoderm pain treatment. The proposed settlement must be ratified by a court.

Endo said it is not required to make any monetary payment to the FTC and made no admission of liability. It said the settlement is "consistent with the company's position that the Lidoderm and Opana ER settlements fully complied with the law both at the time they were executed and today."

Watson and Impax were also named in the FTC's lawsuit, which alleges the companies illegally blocked access to low-cost alternatives to Endo's products. The complaint against those companies remains outstanding.

Watson, which was formerly owned by Allergan Plc (>> Allergan, Inc.), is now owned by Teva Pharmaceutical Industries Ltd (>> Teva Pharmaceutical Industries Limited). Teva and Allergan declined to comment. A spokesman for Impax was not immediately reachable.

(Additional reporting by Diane Bartz; Editing by Bernadette Baum, Bernard Orr)

By Toni Clarke

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
01/23 U.S. FTC reaches pay-for-delay settlement with Endo
01/23 ALLERGAN : Position Increased by Mitsubishi Ufj Trust & Banking Corp
01/20 ALLERGAN : Richter, Allergan sign distribution, supply agreement
01/19 ALLERGAN : Announces FDA Approval Of RHOFADE™ (Oxymetazoline Hydrochloride..
01/18 ALLERGAN : To pay $15m penalty over merger
01/17 Allergan to pay $15 million over failing to disclose merger talks
01/17 ALLERGAN : and Gedeon Richter Announce Positive Phase III Results for Ulipristal..
01/16 ALLERGAN : Big pharma establishes new industry standards group
01/10 ALLERGAN : Enters Licensing Agreement with Assembly Biosciences to Obtain Worldw..
01/10 ASSEMBLY BIOSCIENCES (NASDAQ : ASMB) Files An 8-K Entry into a Material Definiti..
More news
Sector news : Pharmaceuticals - NEC
01/23 U.S. FTC reaches pay-for-delay settlement with Endo
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chairman & President
Scott M. Whitcup Chief Scientific Officer & Executive VP-Research
Raymond H. Diradoorian Executive VP-Global Technical Operations
Maria Teresa Hilado Director
Joann Bradley Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.13.00%0
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.0.39%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results